Practice
Featured experience
Hertz $1 billion financing
We advised Hertz on the transactions
Kroger $5 billion accelerated share repurchase
Kroger will receive an initial delivery of approximately 65.6 million shares
PPL $2 billion at-the-market offering
We advised PPL on the offering
Snowflake $2.3 billion convertible notes offering and capped call transactions
The convertible senior notes are due 2027 and 2029
Digicel cash tender offer
We advised Digicel in connection with the cash tender offer
iQIYI $1.5 billion concurrent convertible notes and equity offerings
Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by iQIYI, Inc…
Zynga $874.5 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Zynga Inc…
MicroStrategy $650 million convertible senior notes offering
Davis Polk advised the initial purchaser in connection with a Rule 144A offering by MicroStrategy Incorporated of $650…
NextEra Energy Partners $600 million convertible senior notes offering
Davis Polk acted as special product counsel to the initial purchaser in connection with a Rule 144A offering by NextEra…
Esperion Therapeutics $250 million convertible senior subordinated notes
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Esperion…
Microchip Technology $1.1 billion convertible notes exchanges
Davis Polk is advising the financial adviser to Microchip Technology Incorporated in connection with Microchip’s privately…
LendingTree $872 million secondary offering
Davis Polk advised LendingTree, Inc. in connection with the $872 million secondary offering of 2,955,984 shares of its…
Morgan Stanley restarts financing and structured product programs
Davis Polk advised Morgan Stanley on the recommencement of its SEC-registered financing programs and the related filing of…
NovoCure $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited…